Literature DB >> 8824300

DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex.

H Hiasa1, D O Yousef, K J Marians.   

Abstract

The formation of a topoisomerase-quinolone-DNA ternary complex leads to cell death. We show here that an active strand breakage and reunion activity is required for formation of a norfloxacin-topoisomerase IV-DNA ternary complex that can arrest the progression of replication forks in vitro. Mutant topoisomerases containing either an active site mutation, a quinolone resistance-conferring mutation, or both, could all bind DNA as well as the wild-type, but unlike the wild-type, could not halt replication fork progression. The collision between the replication fork and the frozen topoisomerase converted the cleavable complex to a nonreversible form but did not generate a double-stranded break. Thus, the cytotoxicity of this class of topoisomerase inhibitors likely results from a two-step process: (i) conversion of the frozen topoisomerase-quinolone-DNA ternary complex to an unreversible form; and (ii) generation of a double-strand break by subsequent denaturation of the topoisomerase, perhaps by an aborted repair attempt.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824300     DOI: 10.1074/jbc.271.42.26424

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites.

Authors:  D B Zamble; D A Miller; J G Heddle; A Maxwell; C T Walsh; F Hollfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

3.  Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes.

Authors:  George Hong; Kenneth N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

4.  Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.

Authors:  Christine D Hardy; Nicholas R Cozzarelli
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  Replacement of ParC alpha4 helix with that of GyrA increases the stability and cytotoxicity of topoisomerase IV-quinolone-DNA ternary complexes.

Authors:  Emily S Pfeiffer; Hiroshi Hiasa
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

6.  Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus.

Authors:  T Niga; H Yoshida; H Hattori; S Nakamura; H Ito
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

7.  Replicative helicases can translocate through abasic site-induced covalent topoisomerase IV-DNA complexes.

Authors:  M E Shea; H Hiasa
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

8.  Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.

Authors:  Carolina de Miranda Silva; Amirhossein Hajihosseini; Jenny Myrick; Jocelyn Nole; Arnold Louie; Stephan Schmidt; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

9.  Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  Philip Chung; Patrick J McNamara; Jeffrey J Campion; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

10.  Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.

Authors:  X S Pan; G Yague; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.